Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126501361 | 12650136 | 1 | I | 20160801 | 20160813 | 20160813 | EXP | GB-CLARIS PHARMASERVICES-1056277 | CLARIS | ^GOLDIE FC, BROGAN A, BOYLE JG. CIPROFLOXACIN AND STATIN INTERACTION: A CAUTIONARY TALE OF RHABDOMYOLYSIS. BMJ CASE REP. 2016 JUL 28;2016. PII: BCR2016216048. DOI: 10.1136/BCR-2016-216048.^ | 62.00 | YR | F | Y | 0.00000 | 20160813 | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126501361 | 12650136 | 1 | PS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | 78062 | ||||||||||||
| 126501361 | 12650136 | 2 | SS | SIMVASTATIN. | SIMVASTATIN | 1 | Oral | Y | 0 | 40 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126501361 | 12650136 | 1 | Urinary tract infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126501361 | 12650136 | OT |
| 126501361 | 12650136 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126501361 | 12650136 | Drug interaction | |
| 126501361 | 12650136 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |